Clinical Trials

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

SCCA Lymphoma Clinical Trials

Brentuximab Vedotin for Non-Hodgkin Lymphoma (UW11026)
A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)
Status Conditions Phase Study ID
Closed Non-Hodgkin's Lymphoma Phase II UW11026

This is a single-arm, open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL).

Andrei Shustov, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Histologically-confirmed CD30-positive NHL
  • Relapsed or refractory disease following at least 1 prior systemic therapy
  • Measurable disease of at least 1.5 cm as documented by CT
  • ECOG performance status less than or equal to 2
Exclusions (conditions that would prevent participation in this study)
  • History of another primary invasive malignancy that has not been in remission for at least 3 years
  • Current diagnosis of systemic or cutaneous anaplastic large cell lymphoma or mycosis fungoides
  • B cell lymphoma previously treated with only single-agent rituximab or corticosteroids as monotherapy
  • Known cerebral/meningeal disease
Last Updated
December 04, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.